Viewing Study NCT04330716


Ignite Creation Date: 2025-12-26 @ 11:49 AM
Ignite Modification Date: 2025-12-26 @ 11:49 AM
Study NCT ID: NCT04330716
Status: COMPLETED
Last Update Posted: 2024-01-19
First Post: 2020-03-17
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers
Sponsor: Dana-Farber Cancer Institute
Organization:

Study Overview

Official Title: Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers - GeneBOPP
Status: COMPLETED
Status Verified Date: 2024-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: GeneBOPP
Brief Summary: This study is evaluating the effect of two pre-test education methods on participants interested in genetic testing for hereditary cancer risk.
Detailed Description: This prospective, randomized controlled trial will evaluate the effect of two pre-test education methods on the level of participation in genetic testing for hereditary cancer risk. A prospective study examines outcomes before the development of a disease.

* The research study procedures include screening for eligibility, randomization and a series of questionnaires.
* Participants will be randomized, or assigned by chance, to one of two methods of pre-genetic test education and after completing either pre-test education participants will be offered the opportunity to have genetic testing performed

Two methods of pre-genetic test education:

* video education
* in-person counseling
* Genetic testing will be performed by blood draw.
* It is expected that 500 people will participate in this study
* Participants will be in the research study for up to 5 yrs after enrollment

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: